- Droplet Biosciences announced it raised $8 million in funding. These are the details.
Droplet Biosciences announced an $8 million seed investment to establish proof of concept for the company’s technology. And while the lymphatic system’s critical role in metastasis has long been recognized, routine access to patient lymph has been elusive.
Droplet’s foundational breakthrough is a non-invasive process to access lymph through the collection of surgical drain fluid after tumor resection. And being rich in T-cells, proteins, and other biomarkers, this lymphatic fluid can offer insights into the body’s immune response to cancer earlier and with greater sensitivity than blood.
The first application is detecting residual disease in head and neck cancer patients immediately after surgery. And earlier and more sensitive residual disease detection enables tailored patient-specific follow-up treatment to reduce cancer recurrence. The financing was led by The Engine, which is the venture firm spun out of MIT that invests in early-stage Tough Tech companies.
Droplet was founded in 2021 by CEO Theresa Tribble and Stan Lapidus along with scientific co-founders Jose Zevallos, MD, MPH, Eugene N. Myers M.D. Chair of Otolaryngology at the University of Pittsburgh and UPMC, and Aadel Chaudhuri, MD, PhD, a leading liquid biopsy researcher and assistant professor of cancer biology, radiation oncology, genetics, computer science, and biomedical engineering at the Washington University in St. Louis. And with backgrounds in diagnostics, surgery, oncology, and genomics, the founding team is combining its hands-on patient experience with breakthrough science to unlock the potential of an enriched biofluid.
Driven by increasing cancer rates, advances in sequencing technology and demand for earlier, non-invasive monitoring across the patient journey, the liquid biopsy market is expected to accelerate significantly over the next decade, with annual growth rates ranging from 12% to 23%. And Droplet’s diagnostic approach is differentiated from current products in the liquid biopsy market because it will deliver earlier and more sensitive results compared to existing blood-based assays.
KEY QUOTES:
“Droplet’s mission is to dramatically improve patient outcomes by leveraging the unique and vital features of lymphatic fluid. Lymph is a minimally explored scientific frontier that can transform the way we identify recurrence risk. Droplet technology will significantly improve on blood-based monitoring diagnostics by aiding clinicians at the most consequential treatment decision point. Additionally, we see massive potential for the lymphatic data coming out of our research to generate new approaches to patient selection and treatment response.”
— Co-founder and CEO Theresa Tribble
“The lymphatic system is the most common route of metastasis in over 90% of cancer cases. As the most proximal biofluid to a recently resected tumor, the lymph contained in surgical drain fluid offers critical information for assessing metastatic risk at the source of potential spread – before it can travel to other parts of the body. Because Droplet’s test takes place immediately after surgery, the results can aid clinicians in adjuvant treatment decisions, unlike blood-based liquid biopsies that can take weeks or even months to identify recurrence risk.”
— Wendy Winckler, PhD, Droplet’s Chief Scientific Officer
“The founders identified a new, important frontier in medicine based on their deep understanding and research into the challenges of treating cancer. We are thrilled to support this team with an equally impressive track record of bringing transformative diagnostics to market.”
— Ann DeWitt, General Partner at The Engine
